Author

Bryant J. Keller

University of Minnesota

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Alex T. LarssoniD· 1 shared Christopher L. MoerteliD· 1 shared David A. LargaespadaiD· 1 shared Garrett M. DraperiD· 1 shared Gunda I. GeorgiD· 1 shared Katherine E. ChaneyiD· 1 shared Kyle Brandon WilliamsiD· 1 shared Minu M. BhuniaiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alex T. LarssonORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumors

Kyle Brandon Williams, Alex T. Larsson, Bryant J. Keller, Katherine E. Chaney, Rory L. Williams, Minu M. Bhunia, Garrett M. Draper, Tyler A. Jubenville, Wendy A. Hudson, Gunda I. Georg, Christopher L. Moertel, Nancy Ratner, David A. Largaespada

This study identifies 23 compounds that selectively kill NF1-deficient Schwann cells and shows their efficacy in vivo, with synergy when combined with Selumetinib.

Molecular Cancer Therapeutics · Oct 1, 2025Peer-reviewedCancer Biology